Trials / Unknown
UnknownNCT05889949
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Prediction of Microvascular Invasion by Radiomics Based on Pre-treatment Magnetic Resonance Imaging (MRI) for Guiding Treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B Hepatocellular Carcinoma (HCC): A Prospective Cohort Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
Conditions
- Radiomics
- Hepatocellular Carcinoma (HCC)
- Transcatheter Arterial Chemoembolization (TACE)
- Microvascular Invasion (MVI)
- Multi-kinase Inhibitors (MKI)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | oral sorafenib |
| DRUG | Lenvatinib | oral lenvatinib |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
- First posted
- 2023-06-05
- Last updated
- 2023-06-07
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05889949. Inclusion in this directory is not an endorsement.